Kelleher Financial Advisors lessened its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 42.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,536 shares of the biopharmaceutical company’s stock after selling 21,573 shares during the quarter. Kelleher Financial Advisors’ holdings in Pfizer were worth $842,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the business. TOWER TRUST & INVESTMENT Co grew its position in Pfizer by 1.9% in the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock worth $551,000 after acquiring an additional 357 shares in the last quarter. Angeles Wealth Management LLC raised its holdings in shares of Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 358 shares in the last quarter. Manchester Financial Inc. raised its holdings in shares of Pfizer by 2.9% during the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 365 shares in the last quarter. Signature Equity Partners LLC lifted its stake in shares of Pfizer by 22.9% in the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 385 shares during the last quarter. Finally, Delta Financial Advisors LLC lifted its stake in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Trading Up 2.6%
Shares of NYSE:PFE opened at $30.79 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock’s 50-day moving average is $28.69 and its 200-day moving average is $26.86. The company has a market cap of $175.52 billion, a P/E ratio of 43.99, a P/E/G ratio of 2.04 and a beta of 0.31. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $31.06.
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The business had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the firm earned $0.87 EPS. The firm’s revenue was down .4% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is currently 226.32%.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the stock. Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Scotiabank boosted their price target on Pfizer from $33.00 to $35.00 and gave the stock a “sector outperform” rating in a research report on Wednesday. Finally, Royal Bank Of Canada upped their price target on Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $29.81.
View Our Latest Research Report on PFE
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS forecast to $2.95–$3.05, citing execution and cost savings. Reuters article
- Positive Sentiment: Growth in newer and acquired medicines is helping offset pandemic-product declines: these products grew 32% operationally in Q3, while non-COVID products overall grew 7%. This supports Pfizer’s effort to build growth beyond COVID sales. The Motley Fool article
- Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling further potential upside. Ticker Report article
- Neutral Sentiment: Pfizer named Cecile Guegan permanent CFO after she served in the interim role. The appointment provides leadership continuity, though its near-term financial impact is unclear. Business Wire announcement
- Negative Sentiment: COVID-related product sales continued to decline, and revenue was slightly lower year over year. UBS and Citi raised their targets to $30 and RBC to $28, but each retained a neutral or sector-perform rating—targets below the recent share price that may temper expectations. UBS rating
Pfizer Company Profile
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.
The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.
Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.
Featured Articles
- Five stocks we like better than Pfizer
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
